VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has applied for patent protection of its novel implantable subcutaneous product and…


Previous articleMindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds
Next articleTryp Therapeutics Announces Q2 2021 Financial Results